Genelux Corp (GNLX) Stock Price, Quote & News

Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and e...

Industry: Biotechnology

Sector: Healthcare

Phone: 805 267 9889

Website: www.genelux.com

Address:

2625 Townsgate Road, Suite 230, Westlake Village, United States

Kupper May. 19 at 4:56 AM

$GNLX no respect for anything good in this world. Shit show made up of shit heads that have no morals or values. Only thing they want is immediate gratification.

0 · Reply

MorganHoratio May. 14 at 12:12 AM

Here are 50 popular stocks compiled by our team; we hope this brings value to my followers.(11-15) $ENVX silicon battery patent fortress $FLNC grid storage contracted backlog $FNGR China mobile data niche $GFS US trailing edge foundry $GNLX oncolytic virus immunotherapy This list maps out the high-stakes "Hard Tech" landscape of 2026! $ENVX’s silicon-anode patent fortress is becoming the power heart of consumer tech, while $FLNC’s record $5.6B backlog secures its dominance in grid storage. Meanwhile, $GFS (GlobalFoundries) remains the anchor for U.S. mature-node sovereignty with strong margin recovery. The wildcard is $GNLX—Phase 3 oncolytic virus data hitting in H2 could be a massive healthcare catalyst. Where do you see the most alpha: the "Energy Anxiety" play or "Semiconductor Sovereignty"? Which of these "special forces" is anchoring your portfolio? Let’s debate!

1 · Reply

justiceforb_85 May. 10 at 9:22 PM

$GNLX wondering why this has done so poorly? Is there concern for dilution? Drug appears active in ovarian ca but wondering why they are going after lung cancer (where there is significant competition)?

0 · Reply

FrodoBag May. 8 at 10:09 PM

$GNLX this tanked when they pushed back top line results to 2H. Now finally above 3 again on news that those results are still on track for 2H…

0 · Reply

bkfViking123 Apr. 28 at 3:30 PM

back in starter shares of $GNLX while it's under the radar ... 2026 is the year if it hits

1 · Reply

Kupper Apr. 21 at 3:21 PM

$GNLX Up one week down the next week. When will this get the attention it deserves.

0 · Reply

OfficialStocktwitsUser Apr. 14 at 3:52 PM

$GNLX RSI: 57.69, MACD: -0.0247 Vol: 0.10, MA20: 2.55, MA50: 2.62 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Kupper Apr. 9 at 3:39 PM

$GNLX what is causing the negative price action on this?

3 · Reply

Kupper Mar. 30 at 7:29 PM

$GNLX this is getting rediculously cheap.

1 · Reply

KC1391 Mar. 30 at 1:46 PM

$GNLX is this a buy again now? Buy low sell high

0 · Reply

Genelux reports Q1 EPS (20c), consensus (19c)

May 7, 2026, 4:15 PM EDT - 11 days ago

Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates

2026-03-20T12:36:29.000Z - 2 months ago

Genelux price target lowered to $20 from $23 at Benchmark

Mar 19, 2026, 4:15 PM EDT - 2 months ago

Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Jan 12, 2026, 4:00 PM EST - 4 months ago

Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

2026-01-08T14:21:22.000Z - 4 months ago

Genelux prices 6.67M shares at $3.00 in underwritten public offering

Jan 8, 2026, 9:13 AM EST - 4 months ago

Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock

2026-01-07T21:05:55.000Z - 4 months ago

Genelux announces common stock offering, no amount given

Jan 7, 2026, 4:01 PM EST - 4 months ago

Genelux Corporation Announces Proposed Public Offering of Common Stock

2026-01-05T15:55:27.000Z - 4 months ago

Genelux data update indicates disease early control, says H.C. Wainwright

2026-01-05T13:25:52.000Z - 4 months ago

Genelux reports interim data of systemic administration of Olvi-Vec

2026-01-02T13:05:23.000Z - 4 months ago

Genelux appoints Jason Litten as CMO

Jan 2, 2026, 8:00 AM EST - 4 months ago

Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

2025-11-05T23:00:37.000Z - 6 months ago

Genelux reports Q3 EPS (21c), consensus (21c)

Nov 5, 2025, 4:20 PM EST - 6 months ago

Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates

2025-10-31T15:55:12.000Z - 7 months ago

Genelux initiated with a Buy at Titan Partners

2025-10-21T17:10:40.000Z - 7 months ago

Genelux price target raised to $20 from $10 at Maxim

REPL

2025-10-21T12:00:50.000Z - 7 months ago

Genelux initiated with a Buy at Lake Street

2025-08-07T22:00:35.000Z - 10 months ago

Genelux reports Q2 EPS (20c), consensus (22c)

Aug 7, 2025, 4:20 PM EDT - 10 months ago

Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates

2025-07-21T11:17:30.000Z - 10 months ago

Genelux initiated with a Buy at Lucid Capital

2025-07-07T11:11:07.000Z - 11 months ago

Genelux appoints Eric Groen as general counsel, corporate secretary, CCO

RANI

Jul 7, 2025, 7:00 AM EDT - 11 months ago

Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

2025-05-06T21:15:11.000Z - 1 year ago

Genelux reports Q1 EPS (21c), consensus (24c)

May 6, 2025, 4:10 PM EDT - 1 year ago

Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates

2025-03-28T20:15:24.000Z - 1 year ago

Genelux reports FY24 EPS (95c), consensus (88c)

Mar 28, 2025, 4:10 PM EDT - 1 year ago

Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

2025-03-25T18:29:53.000Z - 1 year ago

Genelux, Newsoara announce preliminary Phase 1b/2 data of Olvi-Vec

2025-03-25T18:29:16.000Z - 1 year ago

Genelux announces alignment with FDA of approval pathway for Olvi-Vec

2025-03-25T18:26:09.000Z - 1 year ago

Genelux prices 3M shares at $3.50 in underwritten public offering

Mar 25, 2025, 8:31 AM EDT - 1 year ago

Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock

2025-02-19T13:36:46.000Z - 1 year ago

One new option listing on February 19th

Feb 3, 2025, 6:45 AM EST - 1 year ago

Genelux Corporation Announces New Chief Financial Officer

Dec 13, 2024, 7:01 AM EST - 1 year ago

Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright

Nov 6, 2024, 4:01 PM EST - 1 year ago

Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference

Oct 22, 2024, 4:01 PM EDT - 1 year ago

Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer

Oct 9, 2024, 4:15 PM EDT - 1 year ago

Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 3, 2024, 4:01 PM EDT - 1 year ago

Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024

May 24, 2024, 8:00 AM EDT - 2 years ago

Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants

May 23, 2024, 4:01 PM EDT - 2 years ago

Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants

May 9, 2024, 4:25 PM EDT - 2 years ago

Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

$Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer$

Nov 27, 2023, 7:00 AM EST - 2 years ago

Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

Nov 14, 2023, 5:50 PM EST - 2 years ago

Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

Sep 14, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 14, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates

Aug 2, 2023, 4:00 PM EDT - 3 years ago

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2023

Jul 20, 2023, 4:45 PM EDT - 3 years ago

Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires

Jul 10, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology

Jun 29, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC

Jun 22, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023

Jun 12, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation Announces $18 Million Private Placement

$Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) On$

May 25, 2023, 4:01 PM EDT - 3 years ago

Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) On

May 15, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation Announces $33 Million Private Placement

Mar 23, 2023, 7:00 AM EDT - 3 years ago

Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023

Jan 26, 2023, 6:40 AM EST - 3 years ago

Genelux IPO prices at bottom of range

Jan 25, 2023, 9:00 PM EST - 3 years ago

Genelux Corporation Announces Pricing of Initial Public Offering

Sep 19, 2022, 9:08 AM EDT - 3 years ago

Genelux sets IPO terms, as the biotech could be valued at up to $165 millino

Kupper May. 19 at 4:56 AM

$GNLX no respect for anything good in this world. Shit show made up of shit heads that have no morals or values. Only thing they want is immediate gratification.

0 · Reply

MorganHoratio May. 14 at 12:12 AM

1 · Reply

justiceforb_85 May. 10 at 9:22 PM

0 · Reply

FrodoBag May. 8 at 10:09 PM

$GNLX this tanked when they pushed back top line results to 2H. Now finally above 3 again on news that those results are still on track for 2H…

0 · Reply

bkfViking123 Apr. 28 at 3:30 PM

back in starter shares of $GNLX while it's under the radar ... 2026 is the year if it hits

1 · Reply

Kupper Apr. 21 at 3:21 PM

$GNLX Up one week down the next week. When will this get the attention it deserves.

0 · Reply

OfficialStocktwitsUser Apr. 14 at 3:52 PM

0 · Reply

Kupper Apr. 9 at 3:39 PM

$GNLX what is causing the negative price action on this?

3 · Reply

Kupper Mar. 30 at 7:29 PM

$GNLX this is getting rediculously cheap.

1 · Reply

KC1391 Mar. 30 at 1:46 PM

$GNLX is this a buy again now? Buy low sell high

0 · Reply

Shawnkick007 Mar. 25 at 2:05 PM

$GNLX I swear when this thing gets back up to $40 I’m selling this turd.

1 · Reply

anachartanalyst Mar. 20 at 5:02 PM

$GNLX https://anachart.com/wp-content/uploads/ana_temp/1774026109_soc-img.jpg

0 · Reply

Kupper Mar. 3 at 6:45 PM

$GNLX why the drop in share price today?

1 · Reply

BillionerOfKing Mar. 2 at 7:14 PM

$GNLX Current Stock Price: $2.91 Contracts to trade: $5.0 GNLX Mar 20 2026 Call Entry: $0.05 Exit: $0.06 ROI: 31% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

PortfolioOverture Feb. 20 at 2:13 PM

$GNLX Genelux develops oncolytic virus therapies. Clinical milestones are the primary catalyst. Early-stage risk remains high.

0 · Reply

OfficialStocktwitsUser Feb. 12 at 10:32 PM

$GNLX RSI: 32.73, MACD: -0.3002 Vol: 0.19, MA20: 2.66, MA50: 3.47 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BounceRaider Feb. 10 at 1:05 PM

$GNLX is a biotech (Genelux) focused on oncolytic viruses; clinical development is high-risk and capital intensive.

0 · Reply

05ford Feb. 5 at 4:41 AM

$GNLX boy this thing needs a good shot in the arm.

0 · Reply

PLATINUM_TRADES Jan. 16 at 8:04 PM

$GNLX $3.00 Possible on this break of resistance we have another overnight swing winner... Keep it going🚨🚨

0 · Reply

BillionerOfKing Jan. 15 at 11:26 AM

$GNLX Current Stock Price: $2.61 Contracts to trade: $2.5 GNLX Jan 16 2026 Call Entry: $2.34 Exit: $4.10 ROI: 75% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Market Cap	130.93M
Revenue (ttm)	10,000.00
Net Income (ttm)	-32.15M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-321,500.02%
Debt to Equity Ratio	0.00

Volume	161,900
Avg Vol	194,452
Day's Range	N/A - N/A
Shares Out	44.84M
Stochastic %K	26%
Beta	0.51
Analysts	Strong Sell
Price Target	$19.00